Clinical Trial Update: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Sonelokimab for Psoriatic arthritis in biologic DMARD-naive patients; the study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Arthritis, Psoriatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING